RankAlpha logo
Back to Rankings

ALMS

AlumisB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
Bulls can point to the Phase 3 psoriasis win, the favorable safety profile, the 4Q26 NDA path, and the 3Q26 SLE readout as a sequence of value-creating catalysts; secondary post-print coverage also says Chardan, Wells Fargo, and Guggenheim raised targets to $40, $51, and $34, respectively, after Q1 [#SEC-8K-2026-05-14] [#PR-EARNINGS-2026-05-29].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.8.
What can break
Psoriasis NDA timing and FDA feedback may slip; any CRL or label friction would hit the valuation hard.
Momentum
96
Value
41
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $30.00 · Bull $45.00 · Bear $12.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-06 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $40.10
Why
Momentum96 · Δ7d -0.8
Value41 · Δ7d +0.0
Sentiment49 · Δ7d -5.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
96
26% active weight
Current posture
7d trendFlat
Δ7d
-0.8
Δ21d
+14.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
49
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.0
Δ21d
-10.3
Why this grade

Composite grade B. Momentum 95.9 / Value 41.1 / Sentiment 49.0

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$3.65B
Beta
-
Shares Out
127.49M
P/E (TTM) · Derived
-10.0
P/S (TTM)
39.22
P/FCF (TTM) · Derived
-7.45
Rev YoY
-90.0%
EPS YoY
-59.2%
Gross Margin
+58.1%
Op Margin
-1211.9%
Net Debt
-$271.67M
Current Ratio
7.51
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology